Advanced search
Publication Cover
Expert Review of Cardiovascular Therapy Volume 11, 2013 - Issue 10
Submit an article Journal homepage
127
Views
2
CrossRef citations to date
0
Altmetric
Theme: Vascular Disease - Reviews

Revascularization strategies in patients with Type 2 diabetes mellitus

Sharon S ChoiThe Icahn School of Medicine at Mount Sinai, New York, NY, USA
&
Roxana MehranThe Icahn School of Medicine at Mount Sinai, New York, NY, USA;Cardiovascular Research Foundation, New York, NY, USACorrespondence[email protected]
Pages 1337-1347 | Published online: 10 Jan 2014

References

  • Creager MA, Luscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Circulation 108(12), 1527–1532 (2003).
  • Ferreiro JL, Angiolillo DJ. Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation 123(7), 798–813 (2011).
  • Creager MA, Lüscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Circulation 108(12), 1527–1532 (2003).
  • Luscher TF, Creager MA, Beckman JA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. Circulation 108(13), 1655–1661 (2003).
  • Schramm TK, Gislason GH, Kober L et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation 117(15), 1945–1954 (2008).
  • Sobel BE, Frye R, Detre KM. Burgeoning dilemmas in the management of diabetes and cardiovascular disease: rationale for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Circulation 107(4), 636–642 (2013).
  • Anselmino M, Malmberg K, Ohrvik J, Ryden L. Evidence-based medication and revascularization: powerful tools in the management of patients with diabetes and coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. Eur. J. Cardiovasc. Prev. Rehabil. 15(2), 216–223 (2008).
  • Norhammar A, Malmberg K, Ryden L, Tornvall P, Stenestrand U, Wallentin L. Under utilisation of evidence-based treatment partially explains for the unfavourable prognosis in diabetic patients with acute myocardial infarction. Eur. Heart J. 24(9), 838–844 (2003).
  • Otter W, Kleybrink S, Doering W, Standl E, Schnell O. Hospital outcome of acute myocardial infarction in patients with and without diabetes mellitus. Diabet. Med. 21(2), 183–187 (2004).
  • Frye RL, August P, Brooks MM et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N. Engl. J. Med. 360(24), 2503–2515 (2009).
  • Kim LJ, King SB 3rd, Kent K et al. Factors related to the selection of surgical versus percutaneous revascularization in diabetic patients with multivessel coronary artery disease in the BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes) trial. JACC Cardiovasc. Interv. 2(5), 384–392 (2009).
  • Dagenais GR, Lu J, Faxon DP et al. Effects of optimal medical treatment with or without coronary revascularization on angina and subsequent revascularizations in patients with type 2 diabetes mellitus and stable ischemic heart disease. Circulation 123(14), 1492–1500 (2011).
  • Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. N. Engl. J. Med. 335(4), 217–225 (1996).
  • Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status. J. Am. Coll. Cardiol. 35(5), 1122–1129 (2000).
  • BARI Investigators. The final 10-year follow-up results from the BARI randomized trial. J. Am. Coll. Cardiol. 49(15), 1600–1606 (2007).
  • Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 96(6), 1761–1769 (1997).
  • Serruys PW, Ong AT, van Herwerden LA et al. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J. Am. Coll. Cardiol. 46(4), 575–581 (2005).
  • Rodriguez AE, Baldi J, Fernandez Pereira C et al. Five-year follow-up of the Argentine randomized trial of coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple vessel disease (ERACI II). J. Am. Coll. Cardiol. 46(4), 582–588 (2005).
  • Hueb W, Lopes NH, Gersh BJ et al. Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 115(9), 1082–1089 (2007).
  • Booth J, Clayton T, Pepper J et al. Randomized, controlled trial of coronary artery bypass surgery versus percutaneous coronary intervention in patients with multivessel coronary artery disease: six-year follow-up from the Stent or Surgery Trial (SoS). Circulation 118(4), 381–388 (2008).
  • Daemen J, Boersma E, Flather M et al. Long-term safety and efficacy of percutaneous coronary intervention with stenting and coronary artery bypass surgery for multivessel coronary artery disease: a meta-analysis with 5-year patient-level data from the ARTS, ERACI-II, MASS-II, and SoS trials. Circulation 118(11), 1146–1154 (2008).
  • Hannan EL, Racz MJ, Walford G et al. Long-term outcomes of coronary-artery bypass grafting versus stent implantation. N. Engl. J. Med. 352(21), 2174–2183 (2005).
  • Abizaid A, Costa MA, Blanchard D et al. Sirolimus-eluting stents inhibit neointimal hyperplasia in diabetic patients. Insights from the RAVEL Trial. Eur. Heart J. 25(2), 107–112 (2004).
  • Jimenez-Quevedo P, Sabate M, Angiolillo DJ et al. Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial. Eur. Heart J. 28(16), 1946–1952 (2007).
  • Rodriguez AE, Maree AO, Mieres J et al. Late loss of early benefit from drug-eluting stents when compared with bare-metal stents and coronary artery bypass surgery: 3 years follow-up of the ERACI III registry. Eur. Heart J. 28(17), 2118–2125 (2007).
  • Minha S, Bental T, Assali A et al. A comparative analysis of major clinical outcomes using drug-eluting stents versus bare metal stents in diabetic versus nondiabetic patients. Catheter. Cardiovasc. Interv. 78(5), 710–717 (2011).
  • Sinning JM, Baumgart D, Werner N et al. Five-year results of the Multicenter Randomized Controlled Open-Label Study of the CYPHER Sirolimus-Eluting Stent in the Treatment of Diabetic Patients with De Novo Native Coronary Artery Lesions (SCORPIUS) study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients. Am. Heart J. 163(3), 446–453, 53 e1 (2012).
  • Kufner S, de Waha A, Tomai F et al. A meta-analysis of specifically designed randomized trials of sirolimus-eluting versus paclitaxel-eluting stents in diabetic patients with coronary artery disease. Am. Heart J. 162(4), 740–747 (2011).
  • Bangalore S, Kumar S, Fusaro M et al. Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22,844 patient years of follow-up from randomised trials. BMJ 345, e5170 (2012).
  • Park K, Park KW, Rha SW et al. Comparison of 5-year clinical outcomes between sirolimus-versus paclitaxel-eluting stent: Korean multicenter network analysis of 9000-patient cohort. Circ. Cardiovasc. Interv. 5(2), 174–184 (2012).
  • Grube E, Chevalier B, Guagliumi G et al. The SPIRIT V diabetic study: a randomized clinical evaluation of the XIENCE V everolimus-eluting stent vs the TAXUS Liberte paclitaxel-eluting stent in diabetic patients with de novo coronary artery lesions. Am. Heart J. 163(5), 867–875 e1 (2012).
  • Jensen LO, Thayssen P, Junker A et al. Comparison of outcomes in patients with versus without diabetes mellitus after revascularization with everolimus- and sirolimus-eluting stents (from the SORT OUT IV trial). Am. J. Cardiol. 110(11), 1585–1591 (2012).
  • Kim WJ, Lee SW, Park SW et al. Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCE-DIABETES): results from the ESSENCE-DIABETES trial. Circulation 124(8), 886–892.
  • Briguori C, Airoldi F, Visconti G et al. Novel approaches for preventing or limiting events in diabetic patients (Naples-diabetes) trial: a randomized comparison of 3 drug-eluting stents in diabetic patients. Circ. Cardiovasc. Interv. 4(2), 121–129 (2011).
  • Mahmud E, Bromberg-Marin G, Palakodeti V, Ang L, Creanga D, Demaria AN. Clinical efficacy of drug-eluting stents in diabetic patients: a meta-analysis. J. Am. Coll. Cardiol. 51(25), 2385–2395 (2008).
  • Byrne RA, Kastrati A, Massberg S et al. Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial. J. Am. Coll. Cardiol. 58(13), 1325–1231 (2011).
  • Stone GW, Kedhi E, Kereiakes DJ et al. Differential clinical responses to everolimus-eluting and Paclitaxel-eluting coronary stents in patients with and without diabetes mellitus. Circulation 124(8), 893–900 (2011).
  • Tarantini G, Facchin M, Capodanno D et al. Paclitaxel versus sirolimus eluting stents in diabetic patients: does stent type and/or stent diameter matter?: long-term clinical outcome of 2,429-patient multicenter registry. Catheter. Cardiovasc. Interv. 81(1), 80–89 (2013).
  • Stein B, Weintraub WS, Gebhart SP et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation 91(4), 979–989 (1995).
  • Silber S, Serruys PW, Leon MB et al. Clinical outcome of patients with and without diabetes mellitus after percutaneous coronary intervention with the resolute zotarolimus-eluting stent: 2-year results from the prospectively pooled analysis of the international global RESOLUTE program. JACC Cardiovasc. Interv. 6(4), 357–368 (2013).
  • Palmerini T, Dangas G, Mehran R et al. Predictors and implications of stent thrombosis in non-ST-segment elevation acute coronary syndromes: the ACUITY Trial. Circ. Cardiovasc. Interv. 4(6), 577–584 (2011).
  • Kapur A, Hall RJ, Malik IS et al. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. J. Am. Coll. Cardiol. 55(5), 432–440 (2010).
  • Mack MJ, Banning AP, Serruys PW et al. Bypass versus drug-eluting stents at three years in SYNTAX patients with diabetes mellitus or metabolic syndrome. Ann. Thorac. Surg. 92(6), 2140–2146.
  • Onuma Y, Wykrzykowska JJ, Garg S, Vranckx P, Serruys PW. 5-Year follow-up of coronary revascularization in diabetic patients with multivessel coronary artery disease: insights from ARTS (arterial revascularization therapy study)-II and ARTS-I trials. JACC Cardiovasc. Interv. 4(3), 317–323 (2011).
  • Kappetein AP, Head SJ, Morice MC et al. Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial. Eur. J. Cardiothorac. Surg. 43(5), 1006–1013 (2013).
  • Farkouh ME, Domanski M, Sleeper LA et al. Strategies for multivessel revascularization in patients with diabetes. N. Engl. J. Med. 367(25), 2375–2384 (2012).
  • Daemen J, Kuck KH, Macaya C et al. Multivessel coronary revascularization in patients with and without diabetes mellitus: 3-year follow-up of the ARTS-II (Arterial Revascularization Therapies Study-Part II ) trial. J. Am. Coll. Cardiol. 52(24), 1957–1967 (2008).
  • Kappetein AP, Feldman TE, Mack MJ et al. Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. Eur. Heart J. 32(17), 2125–2134 (2011).
  • Mohr FW, Morice MC, Kappetein AP et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 381(9867), 629–638 (2013).
  • Kim WJ, Park DW, Yun SC et al. Impact of diabetes mellitus on the treatment effect of percutaneous or surgical revascularization for patients with unprotected left main coronary artery disease: a subgroup analysis of the MAIN-COMPARE study. JACC Cardiovasc. Interv. 2(10), 956–963 (2009).
  • Dohi S, Kajimoto K, Miyauchi K et al. Comparing outcomes after off-pump coronary artery bypass versus drug-eluting stent in diabetic patients. J. Cardiol. 59(2), 195–201 (2012).
  • Gao F, Zhou YJ, Shen H, Wang ZJ, Yang SW, Liu XL. Meta-analysis of percutaneous coronary intervention versus coronary artery bypass graft surgery in patients with diabetes and left main and/or multivessel coronary artery disease. Acta Diabetol. doi:10.1007/s00592–012-0411–4 (2012) ( Epub ahead of print).
  • Luo Y, Yu X, Chen F et al. Impact of diabetes mellitus on patients with unprotected left main coronary artery lesion disease treated with either percutaneous coronary intervention or coronary-artery bypass grafting. Coron. Artery Dis. 23(5), 322–329 (2012).
  • Hee L, Mussap CJ, Yang L et al. Outcomes of coronary revascularization (percutaneous or bypass) in patients with diabetes mellitus and multivessel coronary disease. Am. J. Cardiol. 110(5), 643–648 (2012).
  • Contini GA, Nicolini F, Fortuna D et al. Five-year outcomes of surgical or percutaneous myocardial revascularization in diabetic patients. Int. J. Cardiol. doi:10.1016/j.ijcard.2012.10.030 (2012) ( Epub ahead of print).
  • Kapur A, Bartolini D, Finlay MC et al. The bypass angioplasty revascularization in type 1 and type 2 diabetes study: 5-year follow-up of revascularization with percutaneous coronary intervention versus coronary artery bypass grafting in diabetic patients with multivessel disease. J. Cardiovasc. Med. (Hagerstown) 11(1), 26–33 (2010).
  • Farkouh ME, Dangas G, Leon MB et al. Design of the Future RE vascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) Trial. Am. Heart J. 155(2), 215–223 (2008).
  • Tonino PA, Fearon WF, De Bruyne B et al. Angiographic versus functional severity of coronary artery stenoses in the FAME study fractional flow reserve versus angiography in multivessel evaluation. J. Am. Coll. Cardiol. 55(25), 2816–2821 (2010).
  • Tonino PA, De Bruyne B, Pijls NH et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N. Engl. J. Med. 360(3), 213–224 (2009).
  • Taggart DP, D'Amico R, Altman DG. Effect of arterial revascularisation on survival: a systematic review of studies comparing bilateral and single internal mammary arteries. Lancet 358(9285), 870–875 (2001).
  • Rizzoli G, Schiavon L, Bellini P. Does the use of bilateral internal mammary artery (IMA) grafts provide incremental benefit relative to the use of a single IMA graft? A meta-analysis approach. Eur. J. Cardiothorac. Surg. 22(5), 781–786 (2002).
  • Kurlansky PA, Traad EA, Dorman MJ, Galbut DL, Zucker M, Ebra G. Thirty-year follow-up defines survival benefit for second internal mammary artery in propensity-matched groups. Ann. Thorac. Surg. 90(1), 101–108 (2010).
  • Savage EB, Grab JD, O'Brien SM et al. Use of both internal thoracic arteries in diabetic patients increases deep sternal wound infection. Ann. Thorac. Surg. 83(3), 1002–1006 (2007).
  • Dorman MJ, Kurlansky PA, Traad EA, Galbut DL, Zucker M, Ebra G. Bilateral internal mammary artery grafting enhances survival in diabetic patients: a 30-year follow-up of propensity score-matched cohorts. Circulation 126(25), 2935–2942 (2012).
  • Borgermann J, Hakim K, Renner A et al. Clampless off-pump versus conventional coronary artery revascularization: a propensity score analysis of 788 patients. Circulation 126(11 Suppl. 1), S176–182 (2012).
  • Halkos ME, Vassiliades TA, Douglas JS et al. Hybrid coronary revascularization versus off-pump coronary artery bypass grafting for the treatment of multivessel coronary artery disease. Ann. Thorac. Surg. 92(5), 1695–1701, discussion 701–702 (2011).
  • Brener SJ, Mehran R, Dressler O, Cristea E, Stone GW. Diabetes mellitus, myocardial reperfusion, and outcome in patients with acute ST-elevation myocardial infarction treated with primary angioplasty (from HORIZONS AMI). Am. J. Cardiol. 109(8), 1111–1116 (2012).
  • Donahoe SM, Stewart GC, McCabe CH et al. Diabetes and mortality following acute coronary syndromes. JAMA 298(7), 765–775 (2007).
  • Wright RS, Anderson JL, Adams CD et al. 2011 ACCF/AHA focused update of the guidelines for the management of patients with unstable angina/non-st-elevation myocardial infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 123(18), 2022–2060 (2011).
  • Wallentin L, Lagerqvist B, Husted S, Kontny F, Stahle E, Swahn E. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease. Lancet 356(9223), 9–16 (2000).
  • Cannon CP, Weintraub WS, Demopoulos LA et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N. Engl. J. Med. 344(25), 1879–1887 (2001).
  • Bassand JP, Hamm CW, Ardissino D et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur. Heart J. 28(13), 1598–1660 (2007).
  • Wijns W, Kolh P, Danchin N et al. Guidelines on myocardial revascularization. Eur. Heart J. 31(20), 2501–2555 (2010).
  • Fihn SD, Gardin JM, Abrams J et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 126(25). 3097–3137 (2012).
  • Stone GW, Witzenbichler B, Guagliumi G et al. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet 377(9784), 2193–2204 (2011).
  • Suh JW, Mehran R, Claessen BE et al. Impact of in-hospital major bleeding on late clinical outcomes after primary percutaneous coronary intervention in acute myocardial infarction the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. J. Am. Coll. Cardiol. 58(17), 1750–1756 (2011).
  • Lopes RD, Subherwal S, Holmes DN et al. The association of in-hospital major bleeding with short-, intermediate-, and long-term mortality among older patients with non-ST-segment elevation myocardial infarction. Eur. Heart J. 33(16), 2044–2053 (2012).
  • Wiviott SD, Braunwald E, Angiolillo DJ et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 118(16), 1626–1636 (2008).
  • Brandt JT, Payne CD, Wiviott SD et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am. Heart J. 153(1), 66 e9–16 (2007).
  • Wiviott SD, Trenk D, Frelinger AL et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial. Circulation 116(25), 2923–2932 (2007).
  • Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357(20), 2001–2015 (2007).
  • Gurbel PA, Bliden KP, Butler K et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 121(10), 1188–1199 (2010).
  • James S, Angiolillo DJ, Cornel JH et al. Ticagrelor vs clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur. Heart J. 31(24), 3006–3016 (2010).
  • Montalescot G, Antoniucci D, Kastrati A et al. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up. Eur. Heart J. 28(4), 443–439 (2007).
  • Roffi M, Topol EJ. Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes. Eur. Heart J. 25(3), 190–198 (2004).
  • Bhatt DL, Marso SP, Lincoff AM, Wolski KE, Ellis SG, Topol EJ. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J. Am. Coll. Cardiol. 35(4), 922–928 (2000).
  • Marso SP, Lincoff AM, Ellis SG et al. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy. Circulation 100(25), 2477–2484 (1999).
  • Montalescot G, Barragan P, Wittenberg O et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N. Engl. J. Med. 344(25), 1895–1903 (2001).
  • Theroux P, Alexander J Jr, Pharand C et al. Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study. Circulation 102(20), 2466–2472 (2000).
  • Moscucci M, Fox KA, Cannon CP et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur. Heart J. 24(20), 1815–1823 (2003).
  • Kinnaird TD, Stabile E, Mintz GS et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am. J. Cardiol. 92(8), 930–935 (2003).
  • Lincoff AM, Bittl JA, Harrington RA et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 289(7), 853–863 (2003).
  • Witzenbichler B, Mehran R, Guagliumi G et al. Impact of diabetes mellitus on the safety and effectiveness of bivalirudin in patients with acute myocardial infarction undergoing primary angioplasty: analysis from the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) trial. JACC Cardiovasc. Interv. 4(7), 760–768 (2011).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.